Ernexa Therapeutics Inc. Other Accrued Liabilities, Current
Ernexa Therapeutics Inc. (ERNA) had Other Accrued Liabilities, Current of $360.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:OtherAccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Other Accrued Liabilities, Current $360.00K.
- 2026-03-31: Other Accrued Liabilities, Current $274.00K.
- 2025-12-31: Other Accrued Liabilities, Current $580.00K; Other Accrued Liabilities, Current as first filed $15.00K.
- 2025-09-30: Other Accrued Liabilities, Current $139.00K.
| Period end | Other Accrued Liabilities, Current | Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $360.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $274.00K 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $580.00K 10-Q · filed 2026-08-06 | $15.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $139.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $438.00K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $460.00K 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $226.00K 10-K · filed 2026-03-13 | $434.00K 10-K · filed 2025-03-12 |
| 2024-09-30 | $463.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $512.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $562.00K 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $508.00K 10-K · filed 2025-03-12 | $490.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | $580.00K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $695.00K 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $520.00K 10-Q · filed 2023-08-11 | $313.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $590.00K 10-K · filed 2024-03-14 | $645.00K 10-K · filed 2023-03-20 |
| 2021-12-31 | $152.00K 10-K · filed 2023-03-20 | |
| 2016-12-31 | $716.00K 10-K · filed 2017-03-09 | |
| 2015-12-31 | $204.00K 10-K · filed 2017-03-09 | $716.00K 10-K · filed 2016-03-15 |
| 2014-12-31 | $204.00K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |